In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
AUTOR(ES)
Pfaller, M. A.
FONTE
American Society for Microbiology
RESUMO
Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as the test medium. Posaconazole was very active against all Candida spp. (MIC at which 90% of the isolates were inhibited [MIC90], 0.5 μg/ml; 97% of MICs were ≤1 μg/ml) and C. neoformans (MIC90, 0.5 μg/ml; 100% of MICs were ≤1 μg/ml). Candida albicans was the most susceptible species of Candida (MIC90, 0.06 μg/ml), and Candida glabrata was the least susceptible (MIC90, 4 μg/ml). Posaconazole was more active than itraconazole and fluconazole against all Candida spp. and C. neoformans. These results provide further evidence for the spectrum and potency of posaconazole against a large and geographically diverse collection of clinically important fungal pathogens.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90743Documentos Relacionados
- Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
- In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
- In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
- Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
- In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.